Elicera Therapeutics AB

Next up in our pipeline series is ELC-401, a CAR T-cell therapy for the initial treatment of brain tumors, armed via our iTANK-platform. Glioblastoma (GBM) is an aggressive brain cancer with a high mortality rate and a lack of effective cures. A major challenge in treating GBM is the blood-brain barrier, which complicates drug delivery, so current treatments are primarily surgery and radiation. ELC-401 targets the tumor antigen IL13Ra2, a receptor protein overrepresented in GBM. Preclinical studies demonstrated that IL13Ra2 is an effective target for iTANK-enhanced CAR T-cells, showing potent cell-killing effects and prolonged survival in disease models. ELC-401 is also expected to counteract the highly immunosuppressive microenvironment in glioblastoma, mobilizing an immune response against other targets. ELC-401 is in the late preclinical evaluation phase, and we are looking for soft funding and/or partnerships to advance the program into clinical development. Find out more about ELC-401: https://lnkd.in/eBCHeJBm #CART #TCellTherapy

Over the next few weeks, we’re going to be running a series of posts spotlighting each of the four drugs in our pipeline!    To kick things off, we’ll start with ELC-301, a CAR T-cell therapy for treatment of diffuse large B-cell lymphoma (DLBCL).    DLBCL is an aggressive cancer originating in B cells. While current standard treatments such as chemotherapy and antibodies cure 60-70% of patients, those who relapse often face limited options.    ELC-301 offers hope through arming with iTANK and targeting CD20, a protein overrepresented in B-cell lymphoma, as opposed to the traditional CD19 target. This innovative approach initially aims to treat patients who relapse and no longer express CD19.    📈 Preclinical success and clinical trials    Preclinical studies show that iTANK-armed CAR T-cells can induce an immune response to destroy cancer cells, even those without the CAR T-cell antigen.    Find out more about ELC-301: https://lnkd.in/eBCHeJBm #CART #TCellTherapy

💼 Invest in CAR T-cell therapy - the future of cancer treatment! CAR T-cell therapy offers potential breakthroughs in cancer treatment thanks to its unique ability to harness the body’s own immune system to attack cancer cells, whilst sparing healthy ones. We recognize the potential for this targeted approach and are leading the way with our innovative iTANK platform, which enhances CAR T-cell therapies' efficacy against solid tumors. Our robust pipeline and innovative technology that helps overcome common barriers position us for significant growth and impact in the oncology field. 🔗 Interested in what we do? Visit our investor page to find out more: https://lnkd.in/gm4ig8iq #CART #TCellTherapy

Elicera Therapeutics has achieved some great things recently and we have continued to develop and grow, establishing ourselves as leaders in the field of CAR T-cell therapy and oncolytic viruses Here are 5 of our recent highlights: 1️⃣ A successful share issue raised SEK 27.6 million, enabling the first clinical trial (CARMA) with our CAR T-cells (ELC-301) armed with the iTANK technology. 2️⃣ CARMA study launched which aims to evaluate ELC-301's safety and efficacy against B-cell malignancies, with plans to treat 18 patients and reach significant milestones in our development program. 3️⃣ Proceeds from the share issue also support the ongoing commercialization of iTANK and further development of our other programs. 4️⃣ We established a partnership with a leading US cancer center to explore expanding iTANK to T-cell receptor therapies (TCR-T). 5️⃣ Our co-founder, Professor Magnus Essand, secured SEK 4.8 million from the Swedish Childhood Cancer Fund to study CAR T-cells' efficacy against brain tumors in children. Explore our annual report: https://lnkd.in/gAw6gmNc Check out our quarterly report: https://lnkd.in/gxvsc3Pk #CARTCellTherapy #Biotech #CellTherapy

A new large-scale study from Stanford Medicine has found that the risk of secondary cancers after CAR-T cell therapy is low and not related to the CAR-T cells themselves.    This news comes after the FDA issued a warning about potential secondary cancer risks earlier in the year. The research confirms that CAR T-cell therapy is a safe and effective treatment and these findings should help alleviate previous concerns.   Read more: https://lnkd.in/dWw4b5bB #CART #Tcelltherapy

We have entered a preclinical collaboration agreement with China Medical University for the development of ELC-201.   This partnership aims to evaluate the efficacy of our oncolytic virus, ELC-201, in preclinical proof-of-concept studies across multiple solid tumour indications.   "We are very pleased to have been able to establish yet another scientific collaboration to advance the development of our unique therapies," says our CEO, Jamal El-Mosleh.   Read the press release: https://lnkd.in/gbv9E-cX

🎗️ It’s #NationalCancerSurvivorsDay ! Today, we celebrate the incredible strength and resilience of cancer survivors around the world. At Elicera Therapeutics, we are dedicated to advancing cancer treatment through our innovative iTANK platform, enhancing the efficacy of CAR T-cell therapies against solid tumors. On this special day, we honor the journey of survivors and reaffirm our commitment to developing groundbreaking therapies that bring hope and healing to those affected by cancer. Learn more about what we do: https://www.elicera.com/

Thank you to our esteemed board member, Margareth Jorvid, for representing Elicera at ISCT in Vancouver and sharing our story on iTANK. #ISCT2024 #celltherapy #genetherapy #ATMP #Elicera #iTANK

Our CEO, Jamal El-Mosleh will be presenting at the Biostock Global Forum in Lund, Sweden!    Taking place on May 29-30, this high-profile event is designed to connect Nordic growth stage companies with a global network of opportunities.   Don’t miss Jamal’s talk on Wednesday 30 May at 11:15, where he will be showcasing Elicera Therapeutics.   We’re looking forward to networking and seeing what opportunities may arise!    If you would like to talk to us at the event, get in touch: info@elicera.com  

Elicera Therapeutics board member, Margareth Jorvid, is heading to Vancouver, Canada, on 29 May – 1 June to participate in the International Society for Cell & Gene Therapy (ISCT) Meeting 2024! 🇨🇦 ISCT 2024 brings together leading researchers, clinicians, and industry experts in cell and gene therapy to share the latest scientific and technological developments in this rapidly developing field. Margareth will participate in a networking session to present our scientific abstract titled "The iTANK platform has potential to improve CAR-T cell treatment of solid tumors." Get in touch if you would like to chat with us: info@elicera.com